Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

被引：26

作者：

Guastafierro, Salvatore ^{[1
]}

Falcone, Umberto ^{[1
]}

Celentano, Maria ^{[1
]}

Coppola, Milena ^{[1
]}

Ferrara, Maria Giovanna ^{[1
]}

Sica, Antonello ^{[1
]}

机构：

[1] Univ Naples 2, Dept Internal Med, Div Haematol, Naples, Italy

来源：

LEUKEMIA RESEARCH | 2009年 / 33卷 / 08期

关键词：

Imatinib mesylate discontinuation; CML; Combination therapy; CHRONIC MYELOGENOUS LEUKEMIA; COMPLETE CYTOGENETIC REMISSION; COMPLETE MOLECULAR REMISSION; INTERFERON-ALPHA; CHRONIC-PHASE; BLAST CRISIS; CML; CYTARABINE; SURVIVAL;

D O I：

10.1016/j.leukres.2008.11.027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case of a 20-years-old male patient in chronic phase CML who maintained undetectable BCR/ABL mRNA levels, despite IM discontinuation over a period of 15 months after achieving CMR. Our patient reached CCyR and CMR after 3 and 6 months of IM treatment, respectively. We also reviewed the published literature concerning cases of IM discontinuation. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1079 / 1081

页数：3

共 21 条

[1] Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) -: Outcome of discontinuation of imatinib therapy after achieving a molecular remission [J].

Ali, R ;

Özkalemkas, F ;

Özçelik, T ;

Özkocaman, V ;

Ozan, Ü ;

Kimya, Y ;

Köksal, N ;

Gülten, T ;

Yakut, T ;

Tunali, A .

LEUKEMIA RESEARCH, 2005, 29 (08) :971-973

[2] Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph plus CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon [J].

Breccia, M. ;

Diverio, D. ;

Pane, F. ;

Nanni, M. ;

Russo, E. ;

Biondo, F. ;

Frustaci, A. ;

Gentilini, F. ;

Alimena, G. .

LEUKEMIA RESEARCH, 2006, 30 (12) :1577-1579

[3] Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia [J].

Burchert, A ;

Wölfl, S ;

Schmidt, M ;

Brendel, C ;

Denecke, B ;

Cai, D ;

Odyvanova, L ;

Lahaye, T ;

Müller, MC ;

Berg, T ;

Gschaidmeier, H ;

Wittig, B ;

Hehlmann, R ;

Hochhaus, A ;

Neubauer, A .

BLOOD, 2003, 101 (01) :259-264

[4] Interferon-α is able to maintain complete molecular remission induced by imatinib after its discontinuation [J].

Carella, A. M. .

LEUKEMIA, 2008, 22 (05) :1090-1091

[5] To the editor: Discontinuation of imatinib therapy after achieving a molecular response [J].

Cortes, J ;

O'Brien, S ;

Kantarjian, H .

BLOOD, 2004, 104 (07) :2204-2205

[6] How I treat chronic myeloid leukemia in the imatinib era [J].

Goldman, John M. .

BLOOD, 2007, 110 (08) :2828-2837

[7] Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia:: Results of a prospective phase II open-label multicenter study [J].

Hess, G ;

Bunjes, D ;

Siegert, W ;

Schwerdtfeger, R ;

Ledderose, G ;

Wassmann, B ;

Kobbe, G ;

Bornhäuser, M ;

Hochhaus, A ;

Ullmann, AJ ;

Kindler, T ;

Hans, U ;

Gschaidmeier, H ;

Huber, C ;

Fischer, T .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7583-7593

[8] Imatinib mesylate-sensitive discontinuation of imatinib blast crisis immediately after mesylate therapy in chronic myelogenous leukemia: Report of two cases [J].

Higashi, T ;

Tsukada, J ;

Kato, C ;

Iwashige, A ;

Mizobe, T ;

Machida, S ;

Morimoto, H ;

Ogawa, R ;

Toda, Y ;

Tanaka, Y .

AMERICAN JOURNAL OF HEMATOLOGY, 2004, 76 (03) :275-278

[9] High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia [J].

Kantarjian, H ;

Talpaz, M ;

O'Brien, SS ;

Garcia-Manero, G ;

Verstovsek, S ;

Giles, F ;

Rios, MB ;

Shan, JQ ;

Letvak, L ;

Thomas, D ;

Faderl, S ;

Ferrajoli, A ;

Cortes, J .

BLOOD, 2004, 103 (08) :2873-2878

[10] Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase - Comparison with historic data [J].

Kantarjian, HM ;

O'Brien, S ;

Cortes, J ;

Giles, FJ ;

Rios, MB ;

Shan, JQ ;

Faderl, S ;

Garcia-Manero, G ;

Ferrajoli, A ;

Verstovsek, S ;

Wierda, W ;

Keating, M ;

Talpaz, M .

CANCER, 2003, 98 (12) :2636-2642

← 1 2 3 →